Cure My Disease

Don't miss your cure!

 Log in / Sign up

New MS drug trial for japanese patients shows promise but study stopped early

NCT ID NCT05265728

Terminated Disease control Sponsor: Biogen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested the drug natalizumab in 21 Japanese adults with relapsing-remitting multiple sclerosis (MS). The goal was to see if injections under the skin every 4 weeks could reduce new brain lesions over 24 weeks, and to check safety for up to 48 weeks. The study was terminated early, so results are limited. Natalizumab is an existing MS treatment that helps control disease but does not cure it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS, RELAPSING-REMITTING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS, RELAPSING-REMITTING

Contacts and locations

Locations

  • Chiba University Hospital

    Chiba, 260-8677, Japan

  • Juntendo University Hospital

    Bunkyō City, 113-8431, Japan

  • Kansai Medical University Medical Center

    Moriguchi-shi, 570-8507, Japan

  • National Center of Neurology and Psychiatry

    Kodaira-shi, 187-8551, Japan

  • National Hospital Organization Hokkaido Medical Center

    Sapporo, 063-0005, Japan

  • Osaka University Hospital

    Suita-shi, 565-0871, Japan

  • St.Marianna University Hospital

    Kawasaki-shi, 216-8511, Japan

  • The Kitasato Institute Kitasato University Hospital

    Sagamihara-shi, 252-0375, Japan

  • Tohoku Medical and Pharmaceutical University Hospital

    Sendai, 983-8512, Japan

  • Tokyo Metropolitan Hospital Organization Tokyo Metropolitan Ebara Hospital

    Ōta-ku, 145-0065, Japan

  • Tokyo Women's Medical University Yachiyo Medical Center

    Yachiyo-shi, 276-8524, Japan

  • University of Tsukuba Hospital

    Tsukuba, 305-8576, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.